Gustavo Rivero, MD
Hematology · Washington, DCNPI 1790736155
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Skeletal Dynamics Inc at 51.4% of the total. Reporting peaked in 2019 at $18,905 and has fallen 74.3% since, to $4,866 in 2025.
Across 59 payments — averaging $485.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Skeletal Dynamics Inc$15K
- Syndax Pharmaceuticals, Inc.$4K
- Agios Pharmaceuticals, Inc.$4K
- E.r. Squibb & Sons, L.L.C.$2K
- Bristol Myers Squibb$2K
- Incyte Corporation$940
- plus $1K from 20 others
Across 16 payments — averaging $3665.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$35K
- Gilead$23K
- Incyte Corporation$1K
What the payments were for
- Consulting fees$6,91024%
- Speaking & faculty fees$3,74013%
- Travel & lodging$15,90956%
- Food & beverage$2,0127%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Skeletal Dynamics Inc | 1 | $14,732 |
| Syndax Pharmaceuticals, Inc. | 4 | $4,391 |
| Agios Pharmaceuticals, Inc. | 11 | $4,034 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,625 |
| Bristol Myers Squibb | 6 | $1,541 |
| Incyte Corporation | 1 | $940 |
| Adaptive Biotechnologies Corporation | 4 | $301 |
| Daiichi Sankyo Inc. | 4 | $158 |
| Pharmaessentia USA Corporation | 1 | $125 |
| AbbVie | 2 | $99 |
| Beone Medicines USA, Inc. | 1 | $95 |
| Novartis | 4 | $92 |
| Sanofi | 2 | $82 |
| Rigel Pharmaceuticals, Inc. | 3 | $75 |
| Legend Biotech USA Inc. | 2 | $64 |
| Apellis Pharmaceuticals, Inc. | 1 | $45 |
| Amgen | 2 | $41 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $39 |
| Teleflex LLC | 1 | $30 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| AstraZeneca | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| GSK | 1 | $21 |
| Eisai Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levofloxacin | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Other hematology in Washington
- Oswaldo CastroWashington$7K
- Donald KarcherWashington$1K
- Mark RoschewskiWashington$356
- Jennifer KanakryWashington$322
- Emily HowardWashington$148
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.